Search Results - gabriele+schilling

7 Results Sort By:
Local Sustained-release Nanocrystal Formulations to Treat and Prevent GI Fibrosis
Unmet Need: Gastrointestinal (GI) fibrosis, the accumulation of scar tissue in the intestinal wall as a complication in common GI autoimmune diseases such as ulcerative colitis (UC) and Crohn’s disease (CD), leads to intestinal strictures, abdominal pain, and reduced intestinal motility. Current pharmacological and surgical treatment methods have significant...
Published: 9/27/2024   |   Inventor(s): Laura Ensign-Hodges, Florin Selaru, Min Kyung Joo, Rachel Shapiro, Ling Li
Keywords(s):  
Category(s): Clinical and Disease Specializations > Gastroenterology
New use of Sulconazole to Treat and Prevent GI Fibrosis
Unmet Need: Gastrointestinal (GI) fibrosis, the accumulation of scar tissue in the intestinal wall as a complication in common GI autoimmune diseases such as ulcerative colitis (UC) and Crohn’s disease (CD), leads to intestinal strictures, abdominal pain, and reduced intestinal motility. Current pharmacological and surgical treatment methods have significant...
Published: 9/27/2024   |   Inventor(s): Florin Selaru, Laura Ensign-Hodges, Ling Li, Min Kyung Joo
Keywords(s):  
Category(s): Clinical and Disease Specializations > Gastroenterology
Locoregional Chemotherapy for Liver Cancers
Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...
Published: 9/26/2024   |   Inventor(s): Florin Selaru, Ling Li
Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer
Liver-directed gene delivery via endoscopic retrograde cholangiopoancreatograpy (ERCP) directed hydrodynamic injection
Unmet NeedGene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of gene therapy trials has been steadily increasing in the United States, with around 170 trials taking place in 2015. All of these trials aim to treat the causes of different diseases instead of only relieving symptoms.  Many...
Published: 9/26/2024   |   Inventor(s): Florin Selaru, Vivek Kumbhari, Ling Li
Keywords(s): Drug Delivery Mechanism, Therapeutic Matter, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
Mini-cancers Utilization as Decision Tools for Personalized Cancer Drug Regimens
The present invention includes methods for identifying chemotherapy treatments specifically suited for each cancer patient. The methods include obtaining a biopsy from the cancer patient; establishing a cancer culture from the biopsy; mixing the cancer culture with a matrix forming mini cancers.  The mini cancers are then used to screen chemotherapy...
Published: 9/26/2024   |   Inventor(s): Florin Selaru, Ling Li
Keywords(s): Assay, Cancers, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, In Vitro Research Tool, Research Instrument, Target-based Screening Tool
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Companion Diagnostics, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Technology Classifications > Research Tools
N171-82Q Huntington's Disease (HD) Mouse Model
C05027: N171-82Q Huntington's Disease (HD) Mouse Model Technical Details: This transgenic line expresses an N-terminally truncated human huntingtin cDNA that encodes 82 glutamines and encompasses the first 171 amino acids. The altered huntingtin cDNA is under the control of a mouse prion protein promoter. Expression is observed in neurons of...
Published: 9/26/2024   |   Inventor(s): Gabriele Schilling, David Borchelt, Christopher Ross
Keywords(s): Cell Lines, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Huntington's Disease, In Vitro Research Tool, In Vivo Research Tool, Mouse Cell Lines, Mouse Model, Neurodegeneration, Translational Research Biomarker
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools
A p105-based NF-(kappa) B Super repressor
C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...
Published: 9/26/2024   |   Inventor(s): Li Lin
Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum